Sudeep Pharma Limited.
Sudeep Pharma IPO: Mumbai, India – November 2025 – Sudeep Pharma Limited, a technology-driven manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries, has successfully raised ₹895 crore through its initial public offering (IPO). The offering consisted of a fresh issue of equity shares and an offer for sale (OFS) by the promoter selling shareholders.
The IPO has drawn significant investor attention, reflecting growing confidence in Sudeep Pharma’s innovative approach to manufacturing critical ingredients for the rapidly expanding sectors of pharmaceuticals, food, and nutrition. The company’s offerings cater to a wide range of applications, including drug formulations and specialized nutrition products, positioning Sudeep Pharma as a key player in the growing demand for high-quality excipients.
Legal Expertise from Leading Law Firms
The legal advisory teams behind the IPO included top law firms: Cyril Amarchand Mangaldas (CAM), S&R Associates, and Hogan Lovells.
Cyril Amarchand Mangaldas advised Sudeep Pharma on the IPO, ensuring comprehensive legal support across all aspects of the transaction. The team was led by Ravi Dubey, Partner and Regional Co-Head of Capital Markets – West, with assistance from Principal Associate Radhika Pandey, along with Associates Esha Gupta, Anomitra Debnath, Harshita Pareek, and Khushi Parek. Their expertise in IPO structuring, regulatory compliance, and documentation played a crucial role in the successful listing.
S&R Associates provided legal counsel to the book running lead managers (BRLMs), ICICI Securities Limited and IIFL Capital Services Limited. The S&R team, led by Partner Jitesh Shahani, worked closely with the BRLMs throughout the offering, providing legal guidance on the IPO process, investor communications, and compliance with Indian securities laws. The team was supported by Principal Associate Ishan Seth, Senior Associate Aditya Jain, and Associates Abhishek Gupta, Aarushi Kapoor, Monisa Mohanty, Sarakshie Sonawane, and Thambiah Jayaram.
Hogan Lovells acted as international legal counsel to the BRLMs, providing valuable expertise in cross-border securities regulations. The team, led by Biswajit Chatterjee, Head of the India Practice and Managing Partner of the Dubai Office, provided critical advice on global compliance issues. Counsel Varun Jetly and Senior Associate Suchisubhra Sarkar supported the international counsel team.
Hogan Lovells.
READ: Pioneer Legal Teams Up with Jurisphere for AI-Powered Legal Solutions
A Milestone for Sudeep Pharma
The ₹895 crore IPO marks a significant milestone for Sudeep Pharma, which has built a strong reputation for its technology-led manufacturing capabilities. As a producer of excipients, which are key inactive ingredients used in drug formulations, and specialty ingredients for the food and nutrition industries, Sudeep Pharma is well-positioned to capitalize on the growing demand for high-quality, safe, and effective raw materials in these sectors.
The funds raised from the IPO will be used to strengthen Sudeep Pharma’s manufacturing capabilities, fund research and development initiatives, and expand its market presence both in India and internationally. The company’s focus on innovation and quality has enabled it to form strategic partnerships with major pharmaceutical and food industry players, further cementing its position in the market.
READ: SAM, AZB Partners Advise on Emirates NBD’s 60% Stake Acquisition in RBL Bank
Investor Confidence in Sudeep Pharma’s Growth Potential
Sudeep Pharma‘s IPO was met with strong demand from institutional and retail investors, underscoring confidence in Sudeep Pharma’s business model and its growth prospects. The company’s expertise in providing specialized ingredients to critical industries like healthcare and nutrition positions it for continued expansion as these sectors evolve.
Sudeep Pharma’s listing on the Indian stock exchanges has attracted significant attention as it reflects the broader trend of increasing investor interest in India’s growing pharmaceutical and food sectors. With a focus on technology-driven solutions, the company is poised to benefit from the rising global demand for high-quality excipients and ingredients in drug manufacturing, dietary supplements, and functional foods.
READ: Supreme Court Clarifies Distinction Between Murder and Attempt to Murder: Why the Ruling Matters
IPO Funding to Fuel Sudeep Pharma’s Growth
With the IPO now complete, Sudeep Pharma is set to continue its growth trajectory, leveraging the capital raised to expand its operations, enhance its product offerings, and strengthen its position in the global market. The company’s commitment to innovation, quality, and sustainability will be key drivers of its success in the competitive landscape of the pharmaceutical and food industries.
For the legal teams involved, this transaction marks another successful milestone in India’s capital markets, highlighting their expertise in managing complex IPOs and supporting companies in their journey to the public markets.
As Sudeep Pharma embarks on the next phase of its growth, the successful IPO and strong market reception are expected to provide a solid foundation for the company’s expansion into new markets and product lines.
READ: Argus Partners Advises on Avaana Capital’s Investment in Wastelink
